FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

Oncology

Source: FDA Center for Drug Evaluation and Research - What's New - September 16, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news